Astrazeneca Pharma India standalone net profit rises 47.54% in the March 2025 quarter
Net profit of Astrazeneca Pharma India rose 47.54% to Rs 58.25 crore in the quarter ended March 2025 as against Rs 39.48 crore during the previous quarter ended March 2024. Sales rose 25.39% to Rs 480.48 crore in the quarter ended March 2025 as against Rs 383.20 crore during the previous quarter ended March 2024.
For the full year,net profit declined 28.34% to Rs 115.74 crore in the year ended March 2025 as against Rs 161.51 crore during the previous year ended March 2024. Sales rose 32.48% to Rs 1716.29 crore in the year ended March 2025 as against Rs 1295.53 crore during the previous year ended March 2024.
| Particulars | Quarter Ended | Year Ended | ||||
| Mar. 2025 | Mar. 2024 | % Var. | Mar. 2025 | Mar. 2024 | % Var. | |
| Sales | 480.48 | 383.20 | 25 | 1716.29 | 1295.53 | 32 |
| OPM % | 17.98 | 12.89 | - | 14.80 | 14.24 | - |
| PBDT | 101.84 | 58.12 | 75 | 293.14 | 218.05 | 34 |
| PBT | 84.15 | 54.36 | 55 | 253.15 | 203.11 | 25 |
| NP | 58.25 | 39.48 | 48 | 115.74 | 161.51 | -28 |